Antonello Mai, University of Rome, Italy

Antonello Mai graduated in Pharmacy in 1984 at the Faculty of Pharmacy of the University of Rome “La Sapienza” with 110/110 cum laude. In June 1992, he obtained the title of PhD in Pharmaceutical Sciences by discussing a thesis entitled “Research on new polycyclic benzodiazepines active on the Central Nervous System”, supervisor the Prof. Marino Artico. In 1998, he was appointed Associate Professor of Medicinal Chemistry at the same University. In 2011, Prof. Mai was appointed Full Professor of Medicinal Chemistry at the Faculty of Pharmacy and Medicine, Sapienza University of Rome. Antonello Mai is Chair Editor of “ChemMedChem” and Associate Editor of “Clinical Epigenetics” and “Journal of Enzyme Inhibition and Medicinal Chemistry “. From 2004 to 2009 Prof. Mai was a member of the Executive Committee of the Pharmaceutical Chemistry Division of the SCI. From 2009 to 2014, he was a member of the Scientific Committee of the European School of Medicinal Chemistry (ESMEC). In 2015 he was a member of the Executive Committee of the European Federation of Medicinal Chemistry (EFMC). From 2012 to 2018, Prof. Mai was the Coordinator of the Doctorate in Pharmaceutical Sciences, belonging to the Doctoral School in Biology and Molecular Medicine (BEMM), in Sapienza University of Rome. From 2013 to 2019, Prof. Mai was the President of the Master’s Degree Course in Medicinal Chemistry and Technology, Faculty of Pharmacy and Medicine, Sapienza University of Rome. Since 2014, Prof. Mai is a member of the Investigation Commission for Research Doctorates of Sapienza University of Rome, which ensures the quality of Sapienza Research Doctorates by preparing them ad hoc for approval by the National Agency for the Evaluation of University and Research (ANVUR). Since 2015 Prof. Mai is System Expert for ANVUR, and since 2019 he is a member of the Quality Team of Sapienza University of Rome. The research activity of prof. Antonello Mai, expressed in 345 publications, 8 patents, 6 book chapters and over 400 communications at conferences, can be referred to four fundamental sectors: a) design and synthesis of small molecules as modulators of epigenetic targets involved in the control of gene transcription (HDACs, HATs, SIRTs, HMTs, HDMs, DNMT). Therapeutic potential in the field of oncology and neurodegenerative and muscular diseases; b) research on active substances on the nervous central system; c) research on substances with antiviral activity (specific inhibitors of HIV-1 reverse transcriptase); d) research on substances with antibacterial, antimicobacterial and antifungal activity. Last interests involve epi-polypharmacology and the use of epi-drugs in parasitic diseases.